The 50% and 95% effective dose of remimazolam tosilate for anaesthesia induction in sleep disorders patients undergoing laparoscopic cholecystectomy: an up-and-down sequential allocation trial.

"Declarations Consent for publicationNot applicable. Ethics approval and consent to participateThis study was approved by the Medical Ethics Committee of The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University ([2022]YLJSA006) on 15 April 2022 and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at Clinicaltrials.gov. (ChiCTR2300069254). Written informed consent about the study protocol was obtained from each patient preoperatively. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was supported by grant no. CJ20210112 from the programme of the Science and Technology Plan of Changzhou City, Jiangsu Province, China."

"This study was approved by the Medical Ethics Committee of The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University ([2022]YLJSA006) on 15 April 2022 and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at Clinicaltrials.gov. (10/03/2023, ChiCTR2300069254). Declarations: Consent for publicationNot applicable.: Ethics approval and consent to participateThis study was approved by the Medical Ethics Committee of The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University ([2022]YLJSA006) on 15 April 2022 and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at Clinicaltrials.gov. (ChiCTR2300069254). Written informed consent about the study protocol was obtained from each patient preoperatively.: Competing interestsThe authors declare no competing interests. Ethics approval and consent to participate: This study was approved by the Medical Ethics Committee of The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University ([2022]YLJSA006) on 15 April 2022 and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at Clinicaltrials.gov. (ChiCTR2300069254). Written informed consent about the study protocol was obtained from each patient preoperatively."